Entries by

Mission Therapeutics to Present at the Mitochondria-Targeted Drug Development Summit

CAMBRIDGE, UK– 26 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Mitochondria-Targeted Drug Development Digital Summit (27-29 April). Paul will present a seminar titled: USP30 Inhibitors: Releasing the Brakes to Improve […]

Mission Therapeutics to Participate in Upcoming SVB Leerink Biopharma Private Company Connect Event

CAMBRIDGE, UK– 22 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Company Connect Event. The event, which will take place virtually on 6-7 May 2021, is intended to […]

Mission Therapeutics Nominates First Development Candidates Targeting USP30

CAMBRIDGE, UK– 25 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has nominated the first two development candidates from its in-house USP30 inhibitor program. USP30 inhibitor candidates MTX652 and MTX114 will be advanced through preclinical good laboratory practice (GLP) toxicology studies during 2021, with […]

Mission Therapeutics Welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors

• Appointment follows Rosetta Capital acquisition of shareholding in Mission from Schroder Adveq CAMBRIDGE, UK– 24 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announces the appointment of Jonathan Hepple to the Company’s Board as a Non-Executive Director. Jonathan is joining Mission’s Board […]

Mission Therapeutics CSO to Present at the Targeted Protein Degradation Europe Summit

CAMBRIDGE, UK– 15 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Targeted Protein Degradation Europe Summit (16-18 March). Paul Thompson will present on 18 March at 14:05 GMT, discussing how deubiquitylating […]

Mission Therapeutics CEO to Present at the Sachs Annual European Life Sciences CEO Forum

CAMBRIDGE, UK– 9 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announced today that Dr Anker Lundemose, CEO, will present at Sachs’ 14th Annual European Life Sciences CEO Forum. Anker Lundemose will present as part of a panel on 11 March at 15:10 CET […]

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

CAMBRIDGE, UK– 2 November 2020 – Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect. Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of […]

Key Appointments Strengthen Mission Therapeutics’ Senior Management Team

CAMBRIDGE, UK– 4 August 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced the promotions of Dr Paul Thompson to CSO and Dr Nick Edmunds to CTO with immediate effect. Dr Paul Thompson (CSO) In his new role, Dr Thompson assumes responsibility for Mission’s […]

Mission and Imperial College London Report Potent and Selective Probe for Deubiquitylating Enzyme UCHL1

LONDON AND CAMBRIDGE, UK – 7 July 2020 – Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics (“Mission”), have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB). The research has been published in the leading peer-reviewed Journal of the American […]

Mission Raises $15m and Expands its Relationship with Pfizer

CAMBRIDGE, UK– 6 July 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (“Pfizer”)(NYSE: PFE). Mission and Pfizer Inc. […]